NEW YORK – Stratify Genomics said on Monday that it has partnered with PWNHealth to offer Stratify's prostate cancer genetic risk test directly to consumers with medical oversight.
Specifically, Stratify and PWNHealth will provide clinical oversight and patient support for Stratify's Prompt Personal Genetic Score (PGS) through the Stratify online portal.
According to the product website, Prompt PGS incorporates the genetic information from "dozens of prostate cancer-risk associated SNPs." Using population-based analyses, the test reports how many men out of 100 with a given genetic score would go on to develop prostate cancer.
The test is designed to provide the knowledge of baseline prostate cancer risk for an informed conversation regarding the risks and benefits of prostate cancer screening, including guidance from clinicians on how often patients should receive prostate specific antigen screening based on individual Prompt PGS results.
"Stratify Genomics is proud to team up with PWNHealth to provide minimally invasive, low-cost tests for prostate cancer risk and potentially save lives through our groundbreaking online telemedicine partnership," Stratify Genomics President Martyn Gross said in a statement. "Previously, family history was the most relied upon method of identifying risk, but now with Prompt PGS, risk is significantly more defined based on a man's genetic profile. This easy-to-use cheek swab test is now readily available to men thanks to our online partnership with PWN."
Stratify follows in the footsteps of several other companies — including Fulgent Genetics, Lineagen, and Sema4 — that have partnered with PWNHealth to directly offer clinician-supported genetic testing to patients.